PROTEIN / TARGET HUNTER

Protein / Target Hunter

Design and Screening of Lead Therapeutic Proteins

The Protein/Target Hunter platform couples AI-based simulations with phage display technology for rapid identification of novel lead therapeutic proteins. Such de novo identification of potential therapeutic molecules facilitates the creation of diverse biologics for many applications.

Tumor immunotherapies utilize single chain variable fragments (scFvs), nanobodies or engineered proteins to target tumor cells and/or to modify the tumor microenvironment (TME). In a collaboration with TMU BIOMED Gloria, GenomeFrontier applies our Protein/Target Hunter platform to identify therapeutic protein leads for specific targeting of tumor antigens and/or TME modulation.

Figure 1. In the Protein/Target Hunter platform machine learning and AI prediction are utilized to generate a highly diverse repertoire of primer sequences for generation of a phage-displayed protein/peptide library. To create the library, the primers are synthesized and annealed to human single-strand phagemid DNA. Following several rounds of biopanning, selected lead(s) are genetically engineered into therapeutic cells using Quantum Engine™ technologies at research scale and evaluated in the GTailor™ platform. Candidates selected in the GTailor™ platform can be incorporated into gene-modified cell therapies or in vivo gene therapies.